Claus Thielert, PhD

InflaRx GmbH
Jena, Thuringen, Germany

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 87 - The safety and efficacy advantage of blocking C5a vs C5 in critically ill, COVID-19 patients: Results from PANAMO, a Phase 3 randomized controlled trial

  Thursday, October 12, 2023
  11:00 AM – 11:15 AM US ET